Our results reveal that AXL–GAS6 signal axis potentially has a key role in NSCLC tumor progression and survival prognosis; and AXL alone or in combination with GAS6 may serve as feasible biomarker for prognostic prediction in patients with metastatic NSCLC to the brain. The gene discussed is GAS6; the disease is non-small cell lung carcinoma.